文献速递心血管胸部MR

因COVID-19住院患者心肌损伤的临床意义:一项前瞻性、多中心、队列研究

Clinical Significance of Myocardial Injury in Patients Hospitalized for COVID-19: A Prospective, Multicenter, Cohort Study.
PubMed 文献 · JACC Cardiovasc Imaging · 2024-08-28

这项在英国25个中心开展的前瞻性纵向队列研究,对342例因COVID-19住院且肌钙蛋白升高的心肌损伤患者进行基线及6个月心脏磁共振随访,并追踪12个月结局。结果显示心肌损伤在中期随访中无进展,主要不良心血管事件发生率低,生活质量改善。

要点

  • COVID-19住院伴肌钙蛋白升高者,6个月随访心肌瘢痕模式和体积无变化(P=0.26)。
  • 12个月内主要不良心血管事件发生率低:死亡1.2%,新发心梗/ACS/血运重建1.8%。
  • 所有心包积液(26/26)消退,多数肺炎(95/101)消退。

核心结论

  • 重症COVID-19住院幸存者的心肌损伤无进展性,中期随访主要不良心血管事件发生率低且生活质量改善。

研究设计与样本

  • 前瞻性纵向队列研究,英国25个中心,2020年6月至2021年3月,342例因COVID-19住院且肌钙蛋白升高的心肌损伤患者,出院后28天内及6个月行心脏磁共振(CMR),随访12个月。

关键影像表现/征象

  • 6个月时左心室射血分数轻度改善(1.8%±1.0%,P<0.001),右心室射血分数稳定(0.4%±0.8%,P=0.50)。
  • 6个月时心肌瘢痕模式和体积无变化(P=0.26),无持续心肌炎症的影像证据。
  • 所有心包积液(26/26)消退,多数肺炎(95/101)消退。

临床应用与阅片要点

  • 对因COVID-19住院且肌钙蛋白升高的患者,出院后28天内及6个月行CMR可评估心肌损伤的转归。
  • 随访CMR显示心肌瘢痕无进展、无持续炎症,提示中期心肌损伤为无进展性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Hospitalized COVID-19 patients with troponin elevation have a higher prevalence of cardiac abnormalities than control individuals. However, the progression and impact of myocardial injury on COVID-19 survivors remain unclear.

OBJECTIVES: This study sought to evaluate myocardial injury in COVID-19 survivors with troponin elevation with baseline and follow-up imaging and to assess medium-term outcomes.

METHODS: This was a prospective, longitudinal cohort study in 25 United Kingdom centers (June 2020 to March 2021). Hospitalized COVID-19 patients with myocardial injury underwent cardiac magnetic resonance (CMR) scans within 28 days and 6 months postdischarge. Outcomes were tracked for 12 months, with quality of life surveys (EuroQol-5 Dimension and 36-Item Short Form surveys) taken at discharge and 6 months.

RESULTS: Of 342 participants (median age: 61.3 years; 71.1% male) with baseline CMR, 338 had a 12-month follow-up, 235 had a 6-month CMR, and 215 has baseline and follow-up quality of life surveys. Of 338 participants, within 12 months, 1.2% died; 1.8% had new myocardial infarction, acute coronary syndrome, or coronary revascularization; 0.8% had new myopericarditis; and 3.3% had other cardiovascular events requiring hospitalization. At 6 months, there was a minor improvement in left ventricular ejection fraction (1.8% ± 1.0%; P < 0.001), stable right ventricular ejection fraction (0.4% ± 0.8%; P = 0.50), no change in myocardial scar pattern or volume (P = 0.26), and no imaging evidence of continued myocardial inflammation. All pericardial effusions (26 of 26) resolved, and most pneumonitis resolved (95 of 101). EuroQol-5 Dimension scores indicated an overall improvement in quality of life (P < 0.001).

CONCLUSIONS: Myocardial injury in severe hospitalized COVID-19 survivors is nonprogressive. Medium-term outcomes show a low incidence of major adverse cardiovascular events and improved quality of life. (COVID-19 Effects on the Heart; ISRCTN58667920).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Shiwani H, Artico J, Moon JC, et al. Clinical Significance of Myocardial Injury in Patients Hospitalized for COVID-19: A Prospective, Multicenter, Cohort Study. JACC Cardiovasc Imaging. 2024. PMID: 39207330. doi:10.1016/j.jcmg.2024.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。